Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives

Article Properties
  • Language
    English
  • DOI (url)
    10.1007/s12325-016-0344-3
  • Publication Date
    2016/05/27
  • Journal
    Advances in Therapy
  • Indian UGC (journal)
  • Refrences
    52
  • Citations
    64
  • Erlinda M. Gordon
  • K. Kumar Sankhala
  • Neal Chawla
  • Sant P. Chawla
Cite
Gordon, Erlinda M., et al. “Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives”. Advances in Therapy, vol. 33, no. 7, 2016, pp. 1055-71, https://doi.org/10.1007/s12325-016-0344-3.
Gordon, E. M., Sankhala, K. K., Chawla, N., & Chawla, S. P. (2016). Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives. Advances in Therapy, 33(7), 1055-1071. https://doi.org/10.1007/s12325-016-0344-3
Gordon EM, Sankhala KK, Chawla N, Chawla SP. Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives. Advances in Therapy. 2016;33(7):1055-71.
Journal Categories
Medicine
Medicine (General)
Medicine
Public aspects of medicine
Toxicology
Poisons
Medicine
Therapeutics
Pharmacology
You May Also Like
Refrences
Title Journal Journal Categories Citations Publication Date
10.1200/JCO.2015.62.4734 2016
Beyond clinical trials in advanced soft tissue sarcoma: what to expect from trabectedin treatment? Future Oncology
  • Medicine: Medicine (General)
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
 1 2015
Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group European Journal of Cancer
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Medicine (General)
 79 2015
10.1016/S1470-2045(15)70098-7 The Lancet Oncology
  • Medicine: Medicine (General)
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
 2015
Trabectedin in Soft Tissue Sarcomas Marine Drugs
  • Science: Biology (General)
  • Medicine: Therapeutics. Pharmacology
  • Medicine: Therapeutics. Pharmacology
  • Medicine: Public aspects of medicine: Toxicology. Poisons
 13 2015
Refrences Analysis
Category Category Repetition
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens35
Medicine: Medicine (General)23
Medicine: Therapeutics. Pharmacology4
Medicine: Public aspects of medicine: Toxicology. Poisons3
Science: Biology (General): Cytology2
Medicine: Gynecology and obstetrics2
Medicine2
Science: Biology (General)1
Medicine: Internal medicine1
Science: Biology (General): Genetics1
The category Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens 35 is the most frequently represented among the references in this article. It primarily includes studies from European Journal of Cancer The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
Title Journal Journal Categories Citations Publication Date
Pegylated liposomal doxorubicin combined with trabectedin as a treatment option in uterine sarcomas: a single-institution retrospective analysis

 International Journal of Gynecologic Cancer
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Gynecology and obstetrics
  • Medicine
  • Medicine: Medicine (General)
 2024
Differences in Sterile Inflammation Incidence After Trabectedin Infusion With Two Central Venous Port Systems: A Retrospective Study Cureus 2024
Emerging pharmaceutical therapies of Ascidian-derived natural products and derivatives Environmental Toxicology and Pharmacology
  • Geography. Anthropology. Recreation: Environmental sciences
  • Medicine: Therapeutics. Pharmacology
  • Medicine: Public aspects of medicine: Toxicology. Poisons
  • Medicine: Public aspects of medicine: Toxicology. Poisons
 2 2023
Advances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects Pharmacology & Therapeutics
  • Medicine: Public aspects of medicine: Toxicology. Poisons
  • Medicine: Therapeutics. Pharmacology
 4 2023
Semisynthesis of 5-O-ester derivatives of renieramycin T and their cytotoxicity against non-small-cell lung cancer cell lines

 Scientific Reports
  • Medicine
  • Science
  • Science: Science (General)
 2023
Citations Analysis
Category Category Repetition
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens21
Medicine: Therapeutics. Pharmacology20
Science: Biology (General)20
Medicine: Public aspects of medicine: Toxicology. Poisons19
Medicine: Medicine (General)17
Science: Biology (General): Genetics9
Science: Biology (General): Cytology8
Science: Chemistry6
Science: Chemistry: General. Including alchemy6
Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy5
Science: Chemistry: Organic chemistry4
Medicine3
Science: Chemistry: Organic chemistry: Biochemistry3
Medicine: Medicine (General): Medical technology2
Science: Microbiology2
Medicine: Gynecology and obstetrics2
Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs2
Geography. Anthropology. Recreation: Environmental sciences1
Medicine: Internal medicine: Special situations and conditions: Sports medicine1
Science: Chemistry: Analytical chemistry1
Technology: Chemical technology: Polymers and polymer manufacture1
Science1
Science: Science (General)1
Medicine: Internal medicine: Infectious and parasitic diseases1
Medicine: Internal medicine1
Technology: Chemical technology: Biotechnology1
Medicine: Other systems of medicine1
The category Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens 21 is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Trial Watch: Immunotherapy plus radiation therapy for oncological indications and was published in 2016. The most recent citation comes from a 2024 study titled Pegylated liposomal doxorubicin combined with trabectedin as a treatment option in uterine sarcomas: a single-institution retrospective analysis. This article reached its peak citation in 2020, with 10 citations. It has been cited in 52 different journals, 44% of which are open access. Among related journals, the Marine Drugs cited this research the most, with 8 citations. The chart below illustrates the annual citation trends for this article.
Citations used this article by year